This Fund is closed to new purchases*
Investing in Canada’s most promising life sciences opportunities, the Fund targets enterprises with defined development and commercialization paths, experienced management teams, and business models focused on delivering increased value in the near future. Investments are diversified across early, mid and late-stage enterprises that the manager believes possess proprietary breakthrough technologies and reduced clinical and regulatory risk profiles.
Fund Information
Management Objective & Strategy
To create long-term capital appreciation driven by investments in select small to medium-sized enterprises operating in Canada's life sciences and biotechnology sectors. Investments are made only in businesses that are considered high-growth investment opportunities primarily inaccessible through the public market.
Advantages of Investment
- Access to high-growth potential of private Canadian enterprises
- Large portfolio of mature and emerging investments
- Investments diversified across key life sciences and biotechnology sectors
- 20% tax credits on each annual contribution
Date of Inception
March 1, 2001
Fund Symbol
Series I - CIG 900
Series II - CIG 901
Series III - CIG 902
Investment Advisor
Genesys Capital Partners
Management Fee
3.45%
Tax Credits
20%
*Effective December 1, 2009 Series II & III are closed to new purchases. The Series remains open to redemptions.
